# A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

> **NCT01773070** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 478 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** ABT-450/ritonavir
- **DRUG:** ABT-333
- **DRUG:** ABT-267

## Key facts

- **NCT ID:** NCT01773070
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773070, "A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01773070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*